Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial
https://pubmed.ncbi.nlm.nih.gov/38777590/
ACTRN12621000654853
A Double-Blind, RandoMised, Placebo-Controlled Study to Assess the
Efficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS)
compared to placebo in participants with symptomatic kneE osteoarthritis
(OA) and dysLipidemia (MaRVeL Study)
https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000654853
Name
Arthropharm Pty Ltd
https://www.arthropharm.com.au/
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-4100
-
- There are more pages in this discussion • 312 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $87.44M |
Open | High | Low | Value | Volume |
25.5¢ | 25.5¢ | 25.0¢ | $8.539K | 33.82K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 29351 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 24579 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4741 | 0.250 |
4 | 39101 | 0.245 |
7 | 118434 | 0.240 |
7 | 65556 | 0.235 |
6 | 208906 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.255 | 52986 | 15 |
0.260 | 6790 | 2 |
0.265 | 5666 | 2 |
0.270 | 21800 | 3 |
0.275 | 15436 | 3 |
Last trade - 12.08pm 28/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
Previous Video
Next Video
SPONSORED BY The Market Online